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Loss-of-Function Mutations in RAB18
Cause Warburg Micro Syndrome
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WarburgMicro syndrome andMartsolf syndrome are heterogenous autosomal-recessive developmental disorders characterized by brain,
eye, and endocrine abnormalities. Previously, identification of mutations in RAB3GAP1 and RAB3GAP2 in both these syndromes
implicated dysregulation of the RAB3 cycle (which controls calcium-mediated exocytosis of neurotransmitters and hormones) in disease
pathogenesis. RAB3GAP1 and RAB3GAP2 encode the catalytic and noncatalytic subunits of the hetrodimeric enzyme RAB3GAP
(RAB3GTPase-activating protein), a key regulator of the RAB3 cycle. We performed autozygosity mapping in five consanguineous
families without RAB3GAP1/2 mutations and identified loss-of-function mutations in RAB18. A c.71T > A (p.Leu24Gln) founder
mutation was identified in four Pakistani families, and a homozygous exon 2 deletion (predicted to result in a frameshift) was found
in the fifth family. A single family whose members were compound heterozygotes for an anti-termination mutation of the stop codon
c.619T > C (p.X207QextX20) and an inframe arginine deletion c.277_279 del (p.Arg93 del) were identified after direct gene sequencing
and multiplex ligation-dependent probe amplification (MLPA) of a further 58 families. Nucleotide binding assays for RAB18(Leu24Gln)
and RAB18(Arg93del) showed that these mutant proteins were functionally null in that they were unable to bind guanine. The clinical
features of Warburg Micro syndrome patients with RAB3GAP1 or RAB3GAP2 mutations and RAB18 mutations are indistinguishable,
although the role of RAB18 in trafficking is still emerging, and it has not been linked previously to the RAB3 pathway. Knockdown
of rab18 in zebrafish suggests that it might have a conserved developmental role. Our findings imply that RAB18 has a critical role in
human brain and eye development and neurodegeneration.Rabs, small G proteins belonging to the Ras superfamily,
precisely coordinate vesicular trafficking in the cell. In
humans, more than 60 RABs dynamically localize to
distinct intracellular membranes, where their recruitment
of effector proteins such as sorting adaptors, kinases,
phosphatases, motors, and tethering factors regulates
membrane identity and vesicle budding, motility, and
fusion. RABs function as molecular switches that alternate
between two conformational states: the GTP-bound
‘‘active’’ form and the GDP-bound ‘‘inactive’’ form. This
allows them to associate and dissociate with target
membranes and regulatemembrane transport in a spatially
and temporarily restricted manner.1,2 The switching of
RAB GTPases is governed by four classes of proteins:
GTPase-activating proteins (GAPs), guanine nucleotide
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epilepsy, and macrocephaly (MIM 300774). Mutations in
RAB7 (MIM 602298) are associated with autosomal-domi-
nant Charcot-Marie-Tooth disease type 2B (MIM 600882).
Functionally, RAB proteins have been classified into
those that regulate the endocytic versus the exocytic
(secretory) pathways.2,3 The RAB3 proteins (RAB3A [MIM
179490]; RAB3B [MIM 179510]; RAB3C [MIM 612829],
and RAB3D [MIM 604350]) modulate calcium-mediated
exocytosis of neurotransmitters and hormones and are
regulated by RAB3GAP.4–7 RAB3GAP is a heterodimeric
complex consisting of a catalytic subunit (p130), which
is encoded by RAB3GAP1 (MIM 602536) on chromosome
2q21.3, and a noncatalytic subunit (p150), encoded by
RAB3GAP2 (MIM 609275) on chromosome 1q41.4,5 Muta-
tions in these genes have been implicated in the pathogen-
esis of two clinically overlapping autosomal-recessive
conditions, Warburg Micro syndrome (MIM 600118) and
Martsolf syndrome (MIM 212720).8–11 Both disorders are
characterized by ocular and neurodevelopmental manifes-
tations; Warburg Micro syndrome is a more severe
disorder.8–14 Recent molecular studies have established
that these two syndromes represent a phenotypic
continuum that appears to be related to the nature and
severity of the mutations present in RAB3GAP1 and RAB3-
GAP2. Severe loss-of-function mutations in RAB3GAP1
have been reported in about 50% (17/35) of Warburg
Micro syndrome patients.8,10 Twomutations have been re-
ported in RAB3GAP2; these are a homozygous frameshift
mutation in a family affected by Warburg Micro syndrome
and a hypomorphic homozygous splicing mutation in
a family affected by Martsolf syndrome.9,11 The cognitive
deficits observed in these disorders are consistent with
the reported role of the RAB3 pathway in cognition. Muta-
tions in RABGDI1 (MIM 300104) (which is a nonspecific
regulator of the RAB3 pathway) cause X-linked mental
retardation,15 and a missense mutation in RIMS1 (MIM
606629) (a downstream effector of RAB3A) has been
implicated in enhanced cognition.16 Furthermore, loss of
rab3gap1 in mice resulted in abnormal release of synaptic
vesicles and altered short-term synaptic plasticity in
the hippocampus; these effects could contribute to the
Warburg Micro cognitive phenotype.17 However, these
mice were viable and fertile and had no structural eye,
brain, or genital abnormalities, suggesting that there is
differential species-specific redundancy in these pathways.
Further locus heterogeneity has been demonstrated for
Warburg Micro and Martsolf syndromes, suggesting that
other genes also play a role in the pathogenesis of these
disorders.8–11
Here, we report the identification and functional charac-
terization of RAB18 mutations in six families affected by
Warburg Micro syndrome. All family members and control
subjects in this study provided written informed consent
under a research protocol approved by the South Birming-
ham Local Research Ethics Committee in accordance with
the Declaration of Helsinki. Genomic DNA was extracted
from venous blood according to standard procedures.500 The American Journal of Human Genetics 88, 499–507, April 8, 2Families 1–5 are consanguineous. Families 1–4 are of
Pakistani origin, and family 5 is Turkish (pedigrees of
families 1–5 are shown in Figure 1). The clinical phenotype
for the families is summarized in Table S1 and is typical of
WarburgMicro syndrome. The eye phenotype in the oldest
affected child from families 1–4 was previously reported.12
All the affected children in these families presented at birth
with congenital cataracts, microphthalmia, and microcor-
nea. In addition, they have small atonic pupils that do not
react to light or mydriatic agents. Despite early cataract
surgery, their vision has remained poor (only light percep-
tion) as a result of progressive optic atrophy and severe
cortical visual impairment (confirmed by normal electrore-
tinogram [ERG] and absent visually evoked potentials
[VEPs]). The progressive neurological deterioration
observed in these children is highlighted in Table S1.
Although they were born with normal head circumfer-
ences (50th–75th percentiles) and develop early mile-
stones, such as smiling, they all have severe truncal
hypotonia such that they have limited head control and,
at the very most, only learn to sit with support. The
children have achieved no developmental milestones
beyond those at the 4 month level; they have not learned
to crawl, pull up to a standing position, or walk. They
developed postnatal acquired microcephaly within the
first year of life, and their head circumferences fell to
between 4SD and 6SD below the mean. Although
some of the younger children have babbled, none have
developed any recognizable words or speech. A character-
istic pattern of progressive lower-limb spasticity started
between 8 and 12months of age, and upper-limb spasticity
developed later, at about 8 years of age. The older children
are profoundly delayed, are wheelchair bound, and have
severe contractures of all four limbs, kyphoscoliosis, and
no voluntary or spontaneous movement. Brain magnetic
resonance imaging (MRI) findings are consistent with
bilateral frontal polymicrogyria and thinning of the corpus
callosum posteriorly in families 2 and 4 (Figure S1). The
brain MRI in family 5 showed bilateral frontal gyration
abnormalities and thinning of the corpus callosum poste-
riorly. Family 6 was reported by Graham et al.14 (as patients
1 and 2) as having typical Warburg Micro syndrome. The
children from this family are the oldest known children
with Warburg Micro syndrome and are aged 21 and 23.
They have both had severe intractable epilepsy with
myoclonic seizures from an early age (2 and 5 years), unlike
the children in families 1–5 (some of whom have general-
ized tonic-clonic seizures). Their brain MRIs also show
bilateral frontal polymicrogyria and thinning, of the
corpus callosum.14 A nerve conduction study in the boy
from family 6 was markedly abnormal due to severe loss
of neurons suggesting an axonal peripheral neuropathy.
Althoughmicrogenitalia in boys has been reported as a dis-
tinguishing feature in families with RAB3GAP1mutations,
the two boys from family 3 had normal genitalia. The
children with RAB18mutations all have facial dysmorphia
similar to that of children with reported RAB3GAP1011
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Figure 1. Fine-Mapping Data for Families 1–5
Microsatellite studies in the extended families confirmed a founder effect in families 1–4. The affected individuals share a common
haplotype between D10S1789 and D10S1228.mutations, as shown in Figure 2. In most families,
antenatal diagnosis by ultrasound has been difficult,
but in family 5, the affected fetus was terminated at
33 weeks after the identification of cataracts and abnormal
brain gyration.
RAB3GAP1 and RAB3GAP2 mutations were excluded in
families 1–5 (by linkage and direct sequencing
[Figure S2]). We then excluded the involvement of other
genes encoding proteins implicated in the RAB3 pathway
(RAB3A, RIMS1, RIMS2 [MIM 606630], RPH3A [MIM
612159], MADD [MIM 603584], WDR7 [MIM 613473],
andDMXL2 [MIM 612186]) by genotyping closely flanking
microsatellite markers (data not shown). We then
performed a genome-wide linkage scan in five large consan-
guineous families by using the 250K SNP arrays (Affyme-
trix) to genotype 11 affected children and four unaffected
siblings. DNAwas amplified and hybridized to the Affyme-
trix 250K SNP chips according to the manufacturer’s
instructions. To further investigate all significant regions
of common homozygosity identified on genome-wide
scan, we genotyped polymorphic UniSTS microsatellite
markers spaced at 1 Mb intervals with GeneMapper soft-
ware. In all the affected children from the five families,
a 10113.089 kb region of shared homozygosity was identi-
fied on chromosome 10p12.1. The region contained 1055
SNPs and was flanked by SNPs rs943124 (20152.733 kb)
and rs3847396 (30265.822 kb) (Figure S3). Families 1–4The Amwere not known to be related but originated from the two
neighboring villages in Pakistan (Mirpur). Interestingly,
they shared a core 6056.698 kb haplotype (containing
680 SNPs) on chromosome 10p12.1 between rs12263288
(24209.124 kb) and rs3847396 (30265.822 kb) (Figure S3).
Microsatellite studies in the extended families confirmed
a founder effect in these families; the affected individuals
shared a common homozygous haplotype between
D10S1789 (23745.855 kb) and D10S1228 (30167.683 kb)
(Figure 1). The genotyping was consistent with linkage;
the parents were heterozygous (as obligate carriers),
and the unaffected siblings had a haplotype different
from that of their affected siblings. A maximum 2-point
LOD score of Z ¼ 8.93 (q ¼ 0 at D10S1749) was calculated
on the assembled haplotypes with GENEHUNTER (version
2.0b) under a model of autosomal-recessive inheritance
with full penetrance; the disease-allele frequency was
estimated at 1 in 1,000, thus confirming linkage to this
region.
The candidate region contained 23 genes (Figure S3).
Intronic primer pairs were designed for exon-specific
amplification of these 23 candidate genes (Figure S3
and Table S2) with Exon Primer. The RAB18 (MIM
602207) primers are shown in Table S3. After PCR amplifi-
cation, sequencing reactions were performed with BigDye
Terminator v3.1 Cycle Sequencing kit and run on an
ABI PRISM 3730 DNA Analyzer (Applied Biosystems). Allerican Journal of Human Genetics 88, 499–507, April 8, 2011 501
Figure 2. Clinical Representation of Patients with Warburg Micro Syndrome at Different Ages
All the children have microcephaly, brachycephaly, microphthalmia, microcornea, low anterior hairline, large protruding pinnae,
and downturned mouth corners. The older children are wheelchair bound and have kyphoscoliosis, severe spastic quadriplegia with
contractures, and diminished muscle bulk.
(1a-f) Affected children from family 3 at 8 months (1a); 15 months (1b), and 18 months (1c,1d, and 1e) show truncal hypotonia; 7 years
(1f and 1g). (2 a and 2b) 18-month-old from family 1. (3a and 3b) 6-year-old from family 5. (4a–4c) 21-year male from family 6; (4d–4f)
23-year-old female from family 6. Permission was obtained from patients’ parents for publication of these images.sequence variants identified were labeled according to the
most abundant RAB18 isoform, which is also present in the
brain (NM_021252.3 or RAB18-001: ENST00000356940).
We carried out multiplex ligation-dependent probe ampli-
fication (MLPA) to detect deletions. Synthetic probes for
exons 1, 1a, 1b, 2, 4, 6, and 7 were designed according to
MRC Holland guidelines (Table S4). Probes that met the
recommended guidelines could not be designed for exons
3, 3a, and 5, and dosage analysis was thus not performed
for these exons. MLPA analysis was carried out according
to MRC Holland’s standard guidelines. Products were
analyzed via the Applied Biosystems ABI 3130xl genetic
analyzer and GeneMarker software (SoftGenetics LLC).
Two independent checks were performed for all results,
and MLPA was repeated, for confirmation, for any patient
found to have an abnormal result.
A germline homozygous missense variant in RAB18
c.71T>A (p.Leu24Gln) was identified in families 1–4502 The American Journal of Human Genetics 88, 499–507, April 8, 2(Figure 3). This sequence variant segregated with disease
status in the families (the parents were heterozygous,
consistent with carrier status, and unaffected siblings had
wild-type sequence or were heterozygous). In family 5,
a homozygous deletion of RAB18 exon 2 was initially de-
tected by PCR (the affected individual did not have an
evident PCR product for exon 2 on agarose gel electropho-
resis). This was then confirmed by MLPA (Figure S4) in the
two affected children. MLPA results for the parents were
consistent with their being heterozygous for this deletion,
and they were thus confirmed as carriers (Figure S5). This
deletion is predicted to result in a frameshift. If the trun-
cated protein were translated and not subject to nonsense-
mediated mRNA decay, it would result in a 25 amino acid
protein (amino acids 1–23 would be wild-type) lacking
the key catalytic RAB domains. We then analyzed a further
58 families affected by Warburg Micro or Martsolf
syndromes for mutations in RAB18 by using direct011
c.669T>C 
c.274_276delAGA
c.71T >A
Deletion
1 2 3 4 5 6 7
A
B
C
Figure 3. RAB18Mutations in Individuals
with Warburg Micro Syndrome
(A) Sequence chromatograms of RAB18
mutations are shown. Affected individuals
(top) and healthy controls (bottom). All
mutations identified are shown with their
amino acid and nucleotide positions
labeled according to NM_021252.3, which
is the only coding transcript in human
brain and retina.
(B) Sequence alignment of the N-terminal
portion of Rab18s from different species.
Sequence identity is indicated in blue,
and sequence similarity is indicated in
red. Switch regions, Leu24, and Arg93 are
labeled, secondary structure is indicated
in cyan, and residues encoded by exon 2
of Homo sapiens RAB18 are enclosed in an
orange box. Sequences were aligned by
the ClustalW algorithm (Thompson et al.,
1994). Accession numbers of sequences
used in the alignment were Homo sapiens
NP_067075; Gallus gallus NP_001006355;
Danio rerio rab18b NP_001003449.1;
Drosophila melanogaster NP_524744.2,
and Caenorhabditis elegans NP_741092.1.
(C) Position of Leu24 and Arg93within the
RAB18 crystal structure. Leu24 and Arg93
are shown in yellow, the GTP analog
GppNP and the magnesium ion are shown
in green, and the switch regions are shown
in red. Molecular coordinates for the
RAB18 crystal structure were taken from
work carried out by Kukimoto-Niino et al.
(RCSB PDB code 1X3S).sequencing and MLPA. Two further RAB18 variants were
detected in both affected siblings of family 6. These
siblings are compound heterozygotes for an in-frame
arginine deletion in exon 7 c.277_279del (p.Arg93del)
and an anti-termination mutation of the stop codon
c.619T>C (p.X207GlnextX20), which is predicted to
extend RAB18 by 20 amino acids and thus abolish
C-terminal prenylation andmembrane targeting (Figure 3).
Their father was shown to be heterozygous for the
p.X207GlnextX20 variant, and their mother was heterozy-
gous for the p.R93 del variant, consistent with theirThe American Journal of Humanbeing obligate carriers. None of the
sequence variants were identified
in 400 ethnically matched control
chromosomes.
The main RAB18 transcript
contains seven exons and encodes
a 206 amino acid protein that is ubiq-
uitously expressed in mammalian
tissues and has particularly high
expression in epithelia and brain.
The first X-ray diffraction crystal of
RAB18 released by Kukimoto-Niino
et al. in 2005 (Protein Data Bank
accession number 1X3S) confirmed
the structural homology of RAB18with other members of the RAB family and showed
that it has the key switch 1 and 2 domains (Figure 3). As
for other RAB proteins, the subcellular localization and
function of RAB18 is determined by its ability to bind
nucleotides. The missense variants p.Leu24Gln and
p.Arg93del both occur in highly conserved amino acid resi-
dues, and their location on folded RAB18 is shown in
Figure 3. The Leu24Gln variant occurs within the
conserved a1 helical domain, 2 amino acids downstream
of the previously published artificially engineered inactive
GDP-bound Ser22Asn mutant RAB18.18 To assess theGenetics 88, 499–507, April 8, 2011 503
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Figure 4. GDP- and GTP-Binding Properties of Wild-Type and
Disease-Associated Mutant Forms of RAB18
(A) Wild-type RAB18 binds GDP similarly to RAB5A and RAB35,
whereas RAB18(Arg93del), RAB18(Leu24Gln) and the negative
control protein GST do bind GDP.
(B) RAB18 binds to GTP, but RAB18(Arg93del) and RAB18
(Leu24Gln) are defective for GTP binding. Error bars indicate the
standard deviation from the mean (n ¼ 3). The bead-bound pool
of theRABs is shown in the stained immunoblots below the graphs.
All are of similar quality and bind to the glutathione beads equally.functional consequences of the missense variants, we
therefore performed nucleotide-binding assays. Wild-type
RAB18;RAB35 (MIM 604199) and RAB5A (MIM 179512)
were cloned into pFAT2 (a His-GST-tagging vectormodified
from pGAT2 to have a polylinker compatible with pQE32),
as described previously.19,20 Several RAB18 transcripts
have been reported, but RT-PCR and sequencing of
human brain, retina, and lymphoblastoid cell lines
identified a single RAB18 transcript that corresponds to
NM_021252.3 (Figure S6). Thus, wild-type and Leu24Gln
mutant transcripts were amplified from patient and
control lymphoblastoid cell lines. The p.Arg93del
mutation was introduced by the Quickchange method
(Stratagene). His-GST-tagged wild-type and mutant RABs
were expressed in E. coli BL21(DE3)-pRIL and bound to
glutathione-sepharose (GE Healthcare) as described previ-
ously.20,21 Glutathione-sepharose-bound RAB proteins
were washed three times at 30C in 50 mM Tris-HCl
(pH 7.4), 150 mMNaCl, and 20 mM EDTA and then eluted
in 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 20 mM
reduced glutathione. For GDP- and GTP-binding assays,
either 2.5 ml of [3H]-GDP (Perkin Elmer) and 10 mM of
Mg2þ-GDP or 0.1 ml of [35S]-GTPgS (Perkin Elmer) and
10 mM of Mg2þ-GTP were loaded into RAB or GST proteins
in 100 ml of reaction mixture (50 mM HEPES-NaOH
[pH 6.8], 125 ml EDTA, 1 mg/ml BSA, and 1 mM DTT) for504 The American Journal of Human Genetics 88, 499–507, April 8, 220 min at 30C. The reactions were stopped by the addi-
tion of 500 ml ice-cold wash buffer (50 mM HEPES-NaOH
[pH 6.8], 150 mM NaCl, and 1 mM MgCl2). Guanosine
-bound RAB proteins were isolated with 20 ml of gluta-
thione-sepharose. The beads were washed three times
with 500 ml of the wash buffer, and scintillation was
counted. The RABs used for the nucleotide binding assays
were of similar quality and bound to the glutathione
beads equally (Figure 4). The nucleotide-binding assays
showed that although RAB18 bound GDP and GTP
comparably to other RABs (RAB5A and RAB35), neither
mutant protein bound detectable levels of either GDP
or GTP (Figure 4). The RAB18 (Leu24Gln) and RAB18
(Arg93del) mutations are therefore functionally null. Their
pathogenicity can be explained by their lack of guanosine
nucleotide binding, because, as for other RAB proteins, this
is a prerequisite for RAB18’s correct subcellular localization
and function.
Because loss-of-function mutations in RAB18 cause
Warburg Micro syndrome, we investigated the effect of
knockdown of rab18 in zebrafish to establish whether
rab18 has a conserved role in brain and eye development.
Zebrafish have two rab18 orthologs: rab18a (ZDB-GENE-
030131-3980, with 81% orthology to human RAB18) and
rab18b (ZDB-GENE-040801-185, with 88% orthology to
the human RAB18). rab18a and rab18b were cloned into
pCS2 from mRNA derived by RT-PCR with total zebrafish
RNA isolated from 24 dpf embryos. Dygoxigenin-labeled
antisense probeswere synthesized as previously described.9
All the primers used are included in Table S5. In situ hybrid-
ization for rab18a and rab18b on whole-mount embryos at
24 and 48 hr showed ubiquitous expression (Figure S7).
Antisense morpholino (MO) oligonucleotides (GeneTools)
targeted to interfere with translation were designed against
both the transcription initiation codonATG and the 50 UTR
region of the rab18a and rab18bmRNA (Table S5). Morpho-
linos (400 pl) were injected into the yolk of one-cell-stage
embryos at a concentrations of 25 mM (84 pg injected/
embryo) and 50 mM (168 pg injected/embryo). As a control
for nonspecific effects, a 5 basemismatch of rab18a-MO1 or
rab18b-MO1morpholinoswas used. Embryoswere raised at
28C and staged in hours (hpf) and days (dpf) post-fertiliza-
tion. Three independent MO injection experiments were
performed for each MO titration. At least 500 injected
embryos were evaluated in total for each MO.
The most common abnormalities observed at 3 dpf
in both the rab18a and rab18b morphants were micro-
phthalmia, microcephaly, pericardial edema, delayed jaw
formation, a reduced overall body size, and a general devel-
opmental delay (Figure S8). Further characterization of
the rab18b (the more conserved ortholog) eye phenotype
revealed that the rab18b morphants had delayed retinal
development and abnormal retinal lamination, residual
nucleated lens fiber cells, widely open choroid fissure,
and microphthalmia at day 3 (Figure S9). To assess the
specificity of the rab18b phenotype, we conducted a rescue
experiment by synthesizing rab18b mRNA. We performed011
the rescue by injecting zygotes with rab18b-MO2 (which is
directed against the 50 UTR) at 25 mM (84 pg injected/
embryo) or 5-mis-rab18b-MO together with rhodamine
dextran (1mg/ml) followed by a consecutive injection, still
at the one-cell stage, with either rab18b mRNA (100 ng)
with CFP (cyan fluorescent protein) mRNA or CFP mRNA
alone. Higher concentrations of mRNA were found to be
toxic. At 24 hpf, we assayed embryos for rhodamine and
CFP fluorescence to select for successfully injected
embryos. Partial rescue of the eye defects (Figures S7, S8,
and S9) pericardial edema and overall developmental
delay (data not shown) was observed at 3 days. The micro-
phthalmia and lens abnormalities would be consistent
with the human eye phenotype. However, further experi-
ments controling for off-target effects (which can be due
to p53 activation), such as insertion of the human
mutations into zebrafish and the creation of zebrafish
transgenics, would clarify the specificity of these observed
phenotypes.
The cellular functions of RAB18 are still emerging, and
the regulators and effectors of the RAB18 cycle have not
yet been identified. Although initial studies in intestinal
and kidney epithelial cells proposed a role for RAB18 in
endocytosis,22 later studies in fibroblasts, neuroendocrine
cells, and adipocytes failed to localize RAB18 to early or
late endosomes. Instead, RAB18 colocalized with specific
markers of lipid droplets (LD) in 3T3-L1 adipocytes;18,23,24
secretory granules in neuroendocrine PC12, AtT20, and
melanotrope cells;25,26 and the cis-Golgi and endoplasmic
reticulum (ER) in NRK, Vero cells, and fibroblasts.27 RAB18
has been shown to act as a negative regulator of the regu-
lated secretory pathway in neuroendocrine cells. Although
RAB3A has a similar role, these proteins associate with
distinct populations of secretory vesicles in neuroendo-
crine cells, suggesting that these two GTPases act at
different steps of the secretory process.25 Further studies
identifying RAB18’s effectors will help to clarify its specific
role as an inhibitor of the secretory or exocytic pathway
and its relationship to RAB3GAP1, RAB3GAP2, and the
RAB3 pathway. Consistent with its role in exocytosis,
RAB18 has been implicated in human disease. RAB18
expression is downregulated in growth-hormone-secreting
pituitary adenomas of patients with acromegaly26. Inter-
estingly, though, none of the Warburg Micro syndrome
patients have growth-hormone or other pituitary defi-
ciencies that would account for their short stature. Several
microarray studies have also shown dysregulation of
RAB18 in neuroendocrine gastointestinal tumors,28 pros-
tate adenocarcinoma,29 breast cancer,30 and pancreatic
adenocarcinoma.31 The exact role of RAB18 in the patho-
physiology of these tumors is not known.
Although a recent study has suggested a distinct role for
RAB18 in the retrograde Golgi-ER pathway in the COPI
(coat protein)-independent pathway,27 previous systematic
screens of all RAB proteins have failed to show a role for
RAB18 in anterograde or retrograde Golgi trafficking.21,32
Interestingly, endogenous RAB18 is the only RAB proteinThe Amthat has been specifically localized to lipid droplets.18 Its
30 terminal is monoprenylated (in comparison to most
other Rab proteins) and undergoes carboxymethylation—
modifications that might increase hydrophobicity and
determine the protein’s specificity for the LD.33 LDs are
formed in the ER and are the primary site for storage of
neutral lipids (including cholesterol) in the cell. They are
dynamic organelles that move around the cell and
distribute lipids to other compartments by using specific
docking machinery.34,35 Overexpression of RAB18 has
recently been shown to induce lipid-droplet association
with the ER in HepG2 cells by expelling adipocyte differen-
tiation-related protein from the lipid droplet.18 Cholesterol
is a major component of lipid droplets, and its several roles
in the developing and adult brain could be important in
WarburgMicro syndromepathogenesis. These roles include
those affecting glial cell proliferation, neurite outgrowth,
microtubule stability, synaptogenesis, myelination, and
signaling. It is a precursor for steroid hormones and is an
indispensable component of nerve cell membranes, in-
cluding the synaptic membrane. Cholesterol also has a
critical role in synaptic-vesicle biogenesis, exocytosis, and
neuronal plasticity.36 Proteomic studies have suggested
that RAB18 is associated with synaptic vesicles, and this
raises the question as to whether RAB18 might play a role
in intracellular lipid trafficking to these vesicles in neurons.
Altered cholesterol trafficking in Warburg Micro syndrome
could thereby account for the exocytosis phenotype
observed with RAB18 and RAB3GAP1. It is also striking
that several brain, eye, and genital malformations seen in
children with Warburg Micro syndrome also occur in a
disorder of cholesterol metabolism, Smith-Lemli-Opitz
(MIM 270400) syndrome.
Previously, no direct link between RAB3 and RAB18
pathways has been reported, but given that loss-of-func-
tionmutations in RAB18 and RAB3GAP1 cause an indistin-
guishable phenotype, it seems likely that there is some
overlap between these pathways. One possibility is that
RAB3GAP1 is not a specific regulator of the RAB3 family
but that it also regulates RAB18. Further functional studies
will help elucidate the connection between these proteins.
It is possible that RAB3GAP1 has additional targets or func-
tions that could be key in the pathogenesis of Warburg
Micro syndrome. Interestingly, plants have orthologs of
the RAB3GAP1 catalytic subunit but lack RAB3 orthologs,
which further supports this idea. No knockout animal
models for rab18 have been described, but our preliminary
zebrafish studies suggest that rab18might have a conserved
developmental role that could account for the structural
abnormalities seen in these syndromes. Clearly, in humans
RAB18 has a key role in eye and brain development and
neurodegeneration.Supplemental Data
Supplemental data include nine figures and five tables and can be
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